Compare FRMM & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRMM | PYPD |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.7M | 71.7M |
| IPO Year | 2017 | 2014 |
| Metric | FRMM | PYPD |
|---|---|---|
| Price | $6.07 | $5.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $5.00 | ★ $12.25 |
| AVG Volume (30 Days) | 180.0K | ★ 183.4K |
| Earning Date | 05-26-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,547,000.00 | N/A |
| Revenue This Year | $183.55 | N/A |
| Revenue Next Year | $166.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.76 | $3.06 |
| 52 Week High | $7.15 | $5.73 |
| Indicator | FRMM | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | 53.59 | 59.61 |
| Support Level | $4.90 | $4.18 |
| Resistance Level | $6.47 | $5.67 |
| Average True Range (ATR) | 0.44 | 0.26 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 71.47 | 96.30 |
Forum Markets Inc is a financial technology company focused on developing infrastructure that supports the origination, financing, and distribution of RWAs through blockchain-enabled capital markets. The company's business approach is centered on integrating traditional financial asset markets with blockchain-based infrastructure to enable the tokenization of income-generating real-world assets such as consumer credit, equipment finance assets, and other contractual cash-flow streams. It utilizes blockchain infrastructure, including Ethereum and related Layer-2 scaling protocols, to support the issuance, management, and potential secondary trading of tokenized financial instruments.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.